Oral Medication May Be Safe, Effective Alternative to Transfusion in Primary Stroke Prevention for Children with Sickle Cell Anemia TCD with Transfusions Changing to
Hydroxyurea (TWiTCH):
Hydroxyurea Therapy as an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia [3]
In addition to establishing a protocol for implementing
hydroxyurea therapy, the guideline addresses changes in pneumococcal vaccination recommendations for adults and children; annual transcranial Doppler screening coupled with long-term transfusion therapy when necessary to prevent stroke in children aged 2-16 years; rapid initiation of opioids for severe pain during vasoocclusive crises; analgesics and physical therapy for avascular necrosis; ACE inhibitor treatment for adults with microalbuminuria; referral to specialists for screening and treatment of proliferative retinopathy; echocardiography to assess signs of pulmonary hypertension; and monitoring for iron overload in patients receiving transfusion therapy.
Systematic review:
Hydroxyurea for the treatment of adults with sickle cell disease.
Those at high risk (history of thrombosis or age >60 years) also receive cytoreductive therapy with
hydroxyurea.
Simultaneous detection of DNA strand breaks and unscheduled DNA synthesis in mutagen-treated human lymphocytes in the absence of
hydroxyurea.
In this observational study, 38 participants suffering from thalassaemia, who were taking
hydroxyurea, were allowed to continue their use of
hydroxyurea but were given one of several homoeopathic medicines.
Experts in the Linus Pauling Institute at Oregon State University say that the study has also shown that chlorophyllin kills cancer cells by blocking the same phase of cellular division that
hydroxyurea does, but by a different mechanism.
Harlem] disease may prompt physicians to treat patients with
hydroxyurea.
He was started on
hydroxyurea, and 1 week after his readmission his platelet count began decreasing.
He was also taking 1,500 mg
hydroxyurea orally twice a day for a recent leukocytosis episode.
This was more successful than
hydroxyurea with longer overall survival rates; notably cytogenetic responses were observed that suggest-ed that the natural history of the disease was being modified.
Study of Videx (didanosine, ddI) and
hydroxyurea shows decreased viral load in patients with HIV